Scroll to top

Archive

CLINUVEL
Posted by CLINUVEL
December 24, 2020

Appendix 3G

Notification of issue, conversion or payment up of equity & securities. Download...

Read More
CLINUVEL
Posted by CLINUVEL
December 22, 2020

Change in substantial holding

22 December 2020 Form 604 Corporations Act 2001 Section 671B Notice of...

Read More
CLINUVEL
Posted by CLINUVEL
December 22, 2020

CLINUVEL Newsletter VI

Dear shareholders, friends, CLINUVEL’S OUTLOOK The past weeks have seen a flurry...

Read More
CLINUVEL
Posted by CLINUVEL
December 15, 2020

SCIENTIFIC COMMUNIQUÉ VIII

DNA Repair Mechanisms  December 2020 Introduction DNA is the repository of genetic...

Read More
CLINUVEL
Posted by CLINUVEL
November 30, 2020

SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED

Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...

Read More
CLINUVEL
Posted by CLINUVEL
November 24, 2020

SCIENTIFIC COMMUNIQUÉ VII

The Cerebral Vasculature System in Disease: Atherosclerosis Introduction The human brain is...

Read More
CLINUVEL
Posted by CLINUVEL
November 20, 2020
CLINUVEL
Posted by CLINUVEL
November 18, 2020

Chair's Letter To Shareholders

19 November 2020 Dear fellow shareholder, I look back at a year...

Read More
CLINUVEL
Posted by CLINUVEL
November 12, 2020
CLINUVEL
Posted by CLINUVEL
November 12, 2020

Results of Annual General Meeting

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...

Read More
CLINUVEL
Posted by CLINUVEL
November 11, 2020

MANAGING DIRECTOR’S PRESENTATION TO CLINUVEL ANNUAL GENERAL MEETING

The following is a transcript of the Managing Director’s presentation to the...

Read More
CLINUVEL
Posted by CLINUVEL
November 11, 2020

CHAIR’S ADDRESS TO CLINUVEL ANNUAL GENERAL MEETING

I am up for re-election today, thank you for those who supported...

Read More
CLINUVEL
Posted by CLINUVEL
October 29, 2020

CLINUVEL Strategic Update – Extended

CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...

Read More
CLINUVEL
Posted by CLINUVEL
October 29, 2020

APPENDIX 4C AND ACTIVITY REPORT

KEY HIGHLIGHTS: SEPTEMBER QUARTER 2020 • Cash receipts of $12,015,000 • Operating...

Read More
CLINUVEL
Posted by CLINUVEL
October 29, 2020

CLINUVEL Strategic Update – Executive Summary

CLINUVEL PHARMACEUTICALS LTD today released a strategic update on its business. An...

Read More
CLINUVEL
Posted by CLINUVEL
October 28, 2020

Afamelanotide for Acute Stroke Patients

EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...

Read More
We use cookies to give you the best experience.